A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)
Status:
Terminated
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to obtain safety information on the use of sitagliptin
phosphate/metformin hydrochloride (HCl) (JANUMET®) from endocrinologists, diabetologists,
internists, and general practitioners.